Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Renalys’ IgAN Drug Nets Positive PIII Data, 2026 Japan Filing on Track
November 27, 2025
- Rolling Submission for Leqembi SC Starting Dose Completed in US
November 27, 2025
- Taisho Touts Low Next-Day Carryover for New Insomnia Drug Vorzzz
November 26, 2025
- Alfresa/Mycenax-Led Biosimilar JV to Be Named Alfenax Biologics
November 26, 2025
- Chugai Targets Japan Filing in 2026 for Ranibizumab Eye Implant
November 26, 2025
- Allergan Japan Files TrenibotE for Glabellar Lines Treatment
November 26, 2025
- Taiho Begins Rolling US NDA Submission for Zipalertinib
November 26, 2025
- Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use
November 26, 2025
- Otsuka Files Novel ADHD Drug Centanafadine in US
November 26, 2025
- Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
November 26, 2025
- Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
November 25, 2025
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+
November 25, 2025
- Kyowa Kirin Begins Japan PIII Trial of Infigratinib for Achondroplasia
November 25, 2025
- Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
November 25, 2025
- Otsuka’s Hypercholesterolemia Med Nexletol Hits Japan Shelves
November 25, 2025
- Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit
November 21, 2025
- 60% of Japan Drug Makers See Lower Operating Profit in H1 FY2025, R&D Costs Weigh on Mid-Sized Firms
November 21, 2025
- ViiV Japan Pushing Digital Tools to Support Patient-Doctor Communication
November 21, 2025
- Japan OKs FoundationOne CDx for Augtyro’s NTRK Fusion Indication
November 21, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…